BUSINESS
Otsuka’s Anti-CGRP Antibody Fremanezumab Smashes Primary Goals in Japan PII/III Studies for Migraine Prevention
Otsuka Pharmaceutical said on January 27 that its anti-calcitonin gene-related peptide (CGRP) antibody fremanezumab (TEV-48125) hit its primary goals in two Japan PII/PIII studies for the prevention of chronic and episodic migraines, according to the preliminary results. Otsuka will determine…
To read the full story
Related Article
- Otsuka Gets Japan Rights to Teva’s Migraine Med
May 16, 2017
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





